STORY CONTINUES BELOW THESE SALTWIRE VIDEOSCOPENHAGEN - Novo Holdings, the controlling shareholder in drugmaker Novo Nordisk, on Thursday said it had closed its acquisition of biopharmaceutical company Paratek Pharmaceuticals in a deal valued at $462 million.
The acquisition of Paratek Pharmaceuticals, which was announced in early June, is Novo Holdings' largest individual investment in antimicrobial resistance therapies to date, it said in a statement. Novo Holdings, which controls 76% of the votes in Denmark's Novo Nordisk last week announced a major investment in a new energy transition fund, as it is looking to expand its portfolio beyond health.
이 소식을 빠르게 읽을 수 있도록 요약했습니다. 뉴스에 관심이 있으시면 여기에서 전문을 읽으실 수 있습니다. 더 많은 것을 읽으십시오: